CAR T-cell Therapy Market Size, Share & Trends Analysis Report By Product (Abecma, Breyanzi, Carvykti, Kymriah), By Disease Indication (Lymphoma, Leukemia, Multiple Myeloma), By End-use, By Region and Segment Forecasts, 2025

The global CAR T-cell therapy market size is estimated to reach USD 15.97 billion by 2030, expanding at a CAGR of 22.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. CAR T-cell therapy presents a paradigm shift in the treatment of blood cancers such as lymphoma, multiple myeloma, and leukemia by utilizing the patient's immune system to terminate cancer cells. The rising prevalence of cancer types such as multiple myeloma in developing countries is driving the market. Rampant regulatory support in the form of product approvals and an intensive product pipeline of drugs further strengthens the industry. For instance, as per the U.S. National Library of Medicine April 2023, around 310 studies pertinent to CAR T-cells are being conducted across early phase I, phase I, and phase II in various parts of the world.

Various players are entering into strategic partnerships along with geographic expansion to necessitate therapy coverage across the world. Thereby, companies are adopting strategies to increase the geographical footprint in countries without access to potential cures or treatments for blood cancers. For instance, on August 31, 2022, Kite, a medical company operating under Gilead announced the expansion of CAR T-cell therapy in regions of Saudi Arabia, Brazil, and Singapore. The company reported an occurrence of 1000 or higher cases of non-Hodgkin lymphoma (NHL) in Singapore, while around 1700 cases of the disease are diagnosed in Saudi Arabia. Similarly, in Brazil, around 12000 cases of NHL are found each year.

The COVID-19 pandemic has made it difficult to administer CAR T-cell therapy to patients, particularly in the early stages of the pandemic when many hospitals and clinics were overwhelmed with COVID-19 patients. Many hospitals had to postpone or cancel elective procedures, including CAR T-cell therapy, to free up resources for COVID-19 patients. In addition, CAR T-cell therapy has significant side effects, including cytokine release syndrome (CRS), which can cause fever, low blood pressure, and organ damage which mimics the symptoms of COVID-19, thereby, curating problems to treat for condition.

Moreover, hospitals and cancer care centers emerging in developing countries are progressing with the adoption of CAR T-cells. These centers thrive as cost and time-efficient cancer treatments allow the market to grow holistically. For instance, in August 2022, Immunotherapy Institute, a cancer treatment center in Mexico began operations to offer CAR T-cells for American and Canadian patients. Similarly, in Israel, the therapy can be expedited in about 10 days owing to the entire process being conducted in-house, with notable cost reductions.

The lack of skilled professionals in emerging nations coupled with the high cost associated with the therapy remain challenges to market growth. However, rising awareness and increasing approvals for technologically advanced CAR T-cell therapy are anticipated to mitigate these challenges and contribute to market growth over the forecast period. According to Cancer Treatment Centers of America, six CAR T-cell therapies were approved by U.S. FDA for the treatment of blood cancers as of 2023.

CAR T-cell Therapy Market Report Highlights:

By product, the Yescarta (axicabtagene ciloleucel) segment dominated the market with a share of 50.0% in 2024. The high usage of Yescarta can be attributed to strong performance and improved survivability in adults suffering from relapsed B-cell large lymphoma
The lymphoma segment held the largest CAR T-cell therapy market share in 2024. The high penetration of the market segment owes itself to the significant prevalence of the condition across the world. Additionally, the strong product focus by market players to eliminate the CD-19 antigen drives growth
By end-use, the hospital segment held the largest share of CAR T-cell therapy industry in 2024 due to the robust presence of fiscal and operational resources. Additionally, in-house labs for hospitals expedite the process faster, helping to gain a strong share
North America accounted for the largest share of 62.1% in 2024. The primary reason for a sizable share can be attributed to the patient volume and overall access to general and complex healthcare, with speedy approvals and robust medical insurance coverage

Product Code: GVR-4-68040-090-4

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Disease Indication
- 1.2.3. End Use
- 1.2.4. Regional Scope
- 1.2.5. Estimates and Forecasts Timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
- 1.4.5. Details of Primary Research
1.5. Information or Data Analysis
- 1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Product Outlook
- 2.2.2. Disease indication Outlook
- 2.2.3. End Use Outlook
- 2.2.4. Regional Outlook
2.3. Competitive Insights

Chapter 3. CAR T-cell Therapy Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. CAR T-cell Therapy Market Analysis tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrant
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political Landscape
  - 3.3.2.2. Technological Landscape
  - 3.3.2.3. Economic Landscape

Chapter 4. CAR T-cell Therapy Market: Product Estimates & Trend Analysis

4.1. Product Segment Dashboard
4.2. CAR T-cell Therapy Market: Product Movement Analysis
4.3. Global CAR T-cell Therapy Market Size & Trend Analysis, By Product, 2018 to 2030 (USD Million)
4.4. Abecma (idecabtagene vicleucel)
- 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.5. Breyanzi (lisocabtagene maraleucel)
- 4.5.1. ket Estimates and Forecasts 2018 to 2030 (USD Million)
4.6. Carvykti (ciltacabtagene autoleucel)
- 4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.7. Kymriah (tisagenlecleucel)
- 4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.8. Tecartus (brexucabtagene autoleucel)
- 4.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.9. Yescarta (axicabtagene ciloleucel)
- 4.9.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.10. Others
- 4.10.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. CAR T-cell Therapy Market: Disease Indication Estimates & Trend Analysis

5.1. Disease Indication Segment Dashboard
5.2. CAR T-cell Therapy Market: Disease Indication Movement Analysis
5.3. Global CAR T-cell Therapy Market Size & Trend Analysis, by Disease Indication, 2018 to 2030 (USD Million)
5.4. Leukemia
- 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.5. Lymphoma
- 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.6. Multiple Myeloma
- 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.7. Others
- 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. CAR T-cell Therapy Market: End Use Estimates & Trend Analysis

6.1. Product Segment Dashboard
6.2. CAR T-cell Therapy Market: End-use Movement Analysis
6.3. Global CAR T-cell Therapy Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Million)
6.4. Hospitals
- 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5. Cancer Treatment Centers
- 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. CAR T-cell Therapy Market: Regional Estimates & Trend Analysis

7.1. Regional Market Dashboard
7.2. Regional Market Share Analysis, 2024 & 2030
7.3. Continuous Bioprocessing Market By Region: Key Takeaways
7.4. North America
- 7.4.1. U.S.
  - 7.4.1.1. Key Country Dynamics
  - 7.4.1.2. Regulatory Framework/ Reimbursement Structure
  - 7.4.1.3. Competitive Scenario
  - 7.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.4.2. Canada
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Regulatory Framework/ Reimbursement Structure
  - 7.4.2.3. Competitive Scenario
  - 7.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5. Europe
- 7.5.1. Germany
  - 7.5.1.1. Key Country Dynamics
  - 7.5.1.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.1.3. Competitive Scenario
  - 7.5.1.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.5.2. UK
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.2.3. Competitive Scenario
  - 7.5.2.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6. Asia Pacific
- 7.6.1. Japan
  - 7.6.1.1. Key Country Dynamics
  - 7.6.1.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.1.3. Competitive Scenario
  - 7.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
- 7.6.2. China
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.2.3. Competitive Scenario
  - 7.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.7. Rest of World

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
- 8.3.1. Key Company Heat Map Analysis, 2024
8.4. Company Profiles
- 8.4.1. Bristol-Myers Squibb Company
  - 8.4.1.1. Company Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Strategic Initiatives
- 8.4.2. Novartis AG
  - 8.4.2.1. Company Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Strategic Initiatives
- 8.4.3. Gilead Sciences, Inc.
  - 8.4.3.1. Company Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Strategic Initiatives
- 8.4.4. Johnson & Johnson Services, Inc.
  - 8.4.4.1. Company Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Strategic Initiatives
- 8.4.5. JW Therapeutics (Shanghai) Co., Ltd.
  - 8.4.5.1. Company Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Strategic Initiatives
- 8.4.6. bluebird bio, Inc.
  - 8.4.6.1. Company Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Strategic Initiatives
- 8.4.7. Merck & Co., Inc.
  - 8.4.7.1. Company Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Strategic Initiatives
- 8.4.8. Sangamo Therapeutics
  - 8.4.8.1. Company Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Strategic Initiatives
- 8.4.9. Sorrento Therapeutics, Inc.
  - 8.4.9.1. Company Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Strategic Initiatives
- 8.4.10. GSK plc.
  - 8.4.10.1. Company Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Strategic Initiatives

Product Code: GVR-4-68040-090-4

List of Tables

Table 1 List of abbreviations
Table 2 North America CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
Table 3 North America CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 4 North America CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 5 North America CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 6 U.S. CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 7 U.S. CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 8 U.S. CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 9 Canada CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 10 Canada CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 11 Canada CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 12 Europe CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
Table 13 Europe CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 14 Europe CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 15 Europe CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 16 Germany CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 17 Germany CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 18 Germany CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 19 UK CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 20 UK CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 21 UK CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 22 Asia Pacific CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
Table 23 Asia Pacific CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 24 Asia Pacific CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 25 Asia Pacific CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 26 Japan CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 27 Japan CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 28 Japan CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 29 China CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 30 China CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 31 China CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 32 Rest of World CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
Table 33 Rest of World CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
Table 34 Rest of World CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
Table 35 Rest of World CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 CAR T-cell therapy market: Market outlook
Fig. 10 CAR T-cell therapy competitive insights
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 Industry value chain analysis
Fig. 15 CAR T-cell therapy market driver impact
Fig. 16 CAR T-cell therapy market restraint impact
Fig. 17 CAR T-cell therapy market strategic initiatives analysis
Fig. 18 CAR T-cell therapy market: Product movement analysis
Fig. 19 CAR T-cell therapy market: Product outlook and key takeaways
Fig. 20 Abecma (idecabtagene vicleucel) market estimates and forecast, 2018 - 2030
Fig. 21 Breyanzi (lisocabtagene maraleucel) market estimates and forecast, 2018 - 2030
Fig. 22 Carvykti (ciltacabtagene autoleucel) market estimates and forecast, 2018 - 2030
Fig. 23 Kymriah (tisagenlecleucel) market estimates and forecast, 2018 - 2030
Fig. 24 Tecartus (brexucabtagene autoleucel) market estimates and forecast, 2018 - 2030
Fig. 25 Yescarta (axicabtagene ciloleucel) market estimates and forecast, 2018 - 2030
Fig. 26 Other market estimates and forecast, 2018 - 2030
Fig. 27 CAR T-cell therapy market: Disease indication movement analysis
Fig. 28 CAR T-cell therapy market: Disease indication outlook and key takeaways
Fig. 29 Leukemia market estimates and forecasts, 2018 - 2030
Fig. 30 Lymphoma market estimates and forecasts,2018 - 2030
Fig. 31 Multiple Myeloma market estimates and forecasts, 2018 - 2030
Fig. 32 Other market estimates and forecasts, 2018 - 2030
Fig. 33 CAR T-cell therapy market: End use movement analysis
Fig. 34 CAR T-cell therapy market: End use outlook and key takeaways
Fig. 35 Hospitals CAR T-cell therapy market estimates and forecast, 2018 - 2030
Fig. 36 Cancer Treatment Centers CAR T-cell therapy estimates and forecast, 2018 - 2030
Fig. 37 Global CAR T-cell therapy market: Regional movement analysis
Fig. 38 Global CAR T-cell therapy market: Regional outlook and key takeaways
Fig. 39 North America market estimates and forecasts, 2018 - 2030
Fig. 40 U.S. market estimates and forecasts, 2018 - 2030
Fig. 41 Canada market estimates and forecasts, 2018 - 2030
Fig. 42 Europe market estimates and forecasts, 2018 - 2030
Fig. 43 Germany market estimates and forecasts, 2018 - 2030
Fig. 44 UK market estimates and forecasts, 2018 - 2030
Fig. 45 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 46 Japan market estimates and forecasts, 2018 - 2030
Fig. 47 China market estimates and forecasts, 2018 - 2030
Fig. 48 Rest of World market estimates and forecasts, 2018 - 2030

CAR T-cell Therapy Market Size, Share & Trends Analysis Report By Product (Abecma, Breyanzi, Carvykti, Kymriah), By Disease Indication (Lymphoma, Leukemia, Multiple Myeloma), By End-use, By Region and Segment Forecasts, 2025 - 2030

Description

Table of Contents

List of Tables

CAR T-cell Therapy Market Growth & Trends:

CAR T-cell Therapy Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. CAR T-cell Therapy Market Variables, Trends & Scope

Chapter 4. CAR T-cell Therapy Market: Product Estimates & Trend Analysis

Chapter 5. CAR T-cell Therapy Market: Disease Indication Estimates & Trend Analysis

Chapter 6. CAR T-cell Therapy Market: End Use Estimates & Trend Analysis

Chapter 7. CAR T-cell Therapy Market: Regional Estimates & Trend Analysis

Chapter 8. Competitive Landscape

List of Tables

List of Figures